Klimek, L. and Olze, H. and Foerster-Ruhrmann, U. and Beule, A. G. and Chaker, A. M. and Hagemann, J. and Huppertz, T. and Hoffmann, T. K. and Dazert, S. and Deitmer, T. and Strieth, S. and Wrede, H. and Schlenter, W. and Welkoborsky, H. J. and Wollenberg, B. and Becker, S. and Klimek, F. and Zuberbier, J. and Rudack, C. and Cuevas, M. and Hintschich, C. A. and Guntinas-Lichius, O. and Stoever, T. and Bergmann, C. and Bachert, C. (2022) Position Paper: Recommendations for the use of mepolizumab in Chronic rhinosinusitis with nasal polyps (CRSwNP) in the German health care system. LARYNGO-RHINO-OTOLOGIE, 101 (04). pp. 284-294. ISSN 0935-8943, 1438-8685
Full text not available from this repository. (Request a copy)Abstract
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the paranasal sinus mucosa with eosinophilic inflammation as the most common endotype. The anti-IL5 antibody mepolizumab was approved for the treatment of severe CRSwNP in the EU in November 2021. Methods A literature search was performed to analyze the immunology of CRSwNP and determine the available evidence by searching Medline, Pubmed, and the German national and international trial and guideline registries and the Cochrane Library. Human studies published in the period up to and including 12/2021 that investigated the effect of mepolizumab in CRSwNP were considered. Results Based on the international literature and previous experience, recommendations for the use of mepolizumab in CRSwNP in the German health care system are given by an expert panel on the basis of a documentation form. Conclusions Understanding about the immunological basis of CRSwNP opens new non-surgical therapeutic approaches with biologics for patients with severe courses. Mepolizumab is approved since November 2021 for add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP who cannot be adequately controlled with systemic corticosteroids and/or surgical intervention.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ENDOSCOPIC SINUS SURGERY; ASTHMA; PHENOTYPES; ALLERGY; ASSOCIATION; INTOLERANCE; POPULATION; OMALIZUMAB; MANAGEMENT; ENDOTYPES; CRS; CRSwNP; Eosinophilie; Sinusitis; T2-Inflammation; Mepolizumab |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Jan 2024 10:20 |
| Last Modified: | 29 Jan 2024 12:45 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58639 |
Actions (login required)
 |
View Item |
